CCG-63802

Research use only, not for human use.

CCG-63802 is a reversible small-molecule inhibitor of regulator of G protein signaling (RGS) proteins.

CCG-63802 is a reversible small-molecule inhibitor of regulator of G protein signaling (RGS) proteins. CCG-63802 inhibits the interaction between RGS4 and Galpha with an IC50 value of 1.4 μM.(In Vitro):CCG-63802 showed selectivity among RGS proteins with a potency order of RGS 4 > 19 = 16 > 8 ? 7. CCG-63802 inhibited the GTPase accelerating protein activity of RGS4.(In Vivo):The attenuating effect of PGZ on airway inflammation, hyperresponsiveness (AHR), and remodeling was partially abrogated by administration of RGS4 inhibitor CCG-63802(0.5 mg/kg). The downregulation of RGS4 by CCG-63802 also significantly increased inflammatory cell accumulation and AHR, and increased levels of IL-4, IL-13, eotaxin, IFN-γ, and IL-17A in BALF, and total and OV-specific IgE in serum. The inhibitory effects of PGZ on the activations of ERK and Akt/mTOR signaling, and MMPs were apparently reversed by CCG-63802 administration.

——

Others

Other Targets

Microtubule/Tubulin

——

——

620112-78-9

450.5

C26H18N4O2S

>98% (HPLC)

——

Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1

——

(-20℃)

With Ice Pack

≥ 2 years